INSTITUTE OF DRUG TECHNOLOGY

AUSTRALIA LIMITED (IDT)

NEWS RELEASE
7 June 2005

FDA APPROVES IDT FACILITY TO MANUFACTURE
THALIDOMIDE FOR CELGENE

Institute of Drug Technology Australia Ltd (IDT) has been granted approval by the US Food and Drug Administration to supply commercial quantities of THALOMID ® (thalidomide) to its client, Celgene Corporation, a U.S. based global biopharmaceutical company. The approval will allow IDT to supply Celgene from its state-of-the-art containment facility at its Boronia complex. IDT established a manufacturing and supply agreement with Celgene in September, 2003.

"Both the FDA and Celgene should be commended for the expertise and diligence which it took to ensure that the IDT facility would be licensed to supply product," commented Dr Graeme Blackman, Chairman and Managing Director of Institute of Drug Technology Australia Ltd. "The FDA approval was a significant win for the Australian pharmaceutical industry and confirmed IDT as a 'world class' GMP manufacturer of highly potent or cytotoxic drugs."

About IDT
Institute of Drug Technology Australia Limited (IDT) is a leading developer and manufacturer of active pharmaceutical ingredients and finished pharmaceutical products for local and international markets. The company also provides a comprehensive range of consultancy, research and development, and analytical services to the pharmaceutical and biotechnology sectors.

Established in 1975, IDT is an Australian-owned public company, listed on the Australian Stock Exchange and employing over 140 highly qualified scientific and support staff. The company has extensive modern manufacturing facilities and laboratories in Melbourne and is licensed by the Australian Therapeutic Goods Administration (TGA) and the United States Food and Drug Administration (FDA) for production of active pharmaceutical ingredients and finished pharmaceutical products. The company has become especially well known internationally for its dedicated facilities for the development and production of anticancer drugs requiring containment. In addition, the company offers early stage clinical trial services from its base at the Royal Adelaide Hospital through its CMAX division.

For further information, please contact:

Dr Graeme Blackman
Chairman & Managing Director
Institute of Drug Technology Australia Limited
Telephone: 61 3 98018888